Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
13 June 2023 | Story Valentino Ndaba | Photo Supplied
GBV UFS Values
Values are a powerful tool in the fight against gender-based violence.

Dr Choice Makhetha, a participant in a recent dialogue focused on the role of student leadership in eradicating gender-based violence (GBV), conveyed a pivotal message during her opening statement. She emphasised universities’ dedication to reshaping and instilling new values in the lives of students. This sentiment laid the foundation for an insightful discussion centred on the importance of values in combating GBV. 

"In university, we work hard to reshape and bring new values into students' lives,” said the Director of Student Affairs at Stellenbosch University, who is a former University of the Free State (UFS) Vice-Rector: External Relations, Dean of Student Affairs, and alumna.

The dialogue was a collaborative effort between the Gender Equality and Anti-Discrimination Office and the Division of Student Affairs. It featured esteemed experts in student governance and leadership, including Sikhululekile Luwaca, Assistant Researcher in the UFS Unit for Institutional Change and Social Justice, Prof Nicky Morgan, former UFS Vice-Rector: Operations, and Moema Motlogelwa, Assistant Director in Student Affairs.

The importance of being value-driven

Luwaca emphasised the need for student leaders to contemplate UFS values. He remarked, "Vision 130 commits us to be accountable. It affirms that those within the UFS will be held accountable. We are devoted to creating an environment that fosters exceptional teaching, learning, and scholarship, as well as caring for ourselves, our fellow human beings, and the natural environment. Our commitment lies in advancing the values of human dignity through ethical and transparent conduct, along with institutional responsibility."

In addition, Luwaca proposed the implementation of a prerequisite course on GBV for all students aspiring to hold positions in the Student Representative Council. This measure would further enhance awareness and understanding of GBV among future leaders.

Echoing similar sentiments, Prof Morgan advocated for justice and respect as fundamental guiding principles in all interactions. “Develop an internal compass of what is right – and that does not depend on laws, politics, or democracy. GBV among our leaders is not a political issue.”

With great power comes great responsibility

Motlogelwa's contribution focused on developing student leaders and addressing gender-based violence (GBV). He highlighted three key steps: awareness and education, advocacy and support, and strengthening partnerships. He emphasised the need for well-informed student leaders who understand university policies and referral systems. Motlogelwa also stressed the importance of advocating and supporting GBV prevention. Additionally, he proposed collaborative efforts with relevant entities to achieve common goals. Ultimately, the goal is to produce model citizens who embody the university's vision and values.

What values do we subscribe to as an institution? 

At the UFS, our values are integral to shaping our culture and guiding our actions and choices. These values include a commitment to excellence, innovation, and impact, as well as accountability, care, and social justice. These principles are articulated in Vision 130, our strategic intent to reposition the institution by the time of its 130th anniversary in 2034.

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept